Eupraxia Pharmaceuticals Inc. EPRX
8.06 USD +0.43 (+5.64%)
At closeNov 12, 2026, 4:13 AM EST
8.06 0.00 0.00%
Pre-market · Nov 12, 4:13 AM ET
7.96 Day range 8.49
5.63 52-week range 9.32
- YTD
- +6.75%
- 1 year
- +23.43%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Raises Price Target to $16 HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and raises the price target from $11 to $16.
benzinga.com Eupraxia Announces $125M At-The-Market Equity Program; Says No Current Plan To Use ATM Program In Near Term Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
globenewswire.com Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…
benzinga.com Eupraxia Pharmaceuticals Q3 EPS $(0.23) Beats $(0.28) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 21.05 percent decrease over…
globenewswire.com Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging…- benzinga.com RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14 RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.
benzinga.com Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the…